John J. Bostjancic - Jan 5, 2023 Form 3 Insider Report for Orthofix Medical Inc. (OFIX)

Role
CFO
Signature
/s/ Patrick Keran, attorney-in-fact
Stock symbol
OFIX
Transactions as of
Jan 5, 2023
Transactions value $
$0
Form type
3
Date filed
1/10/2023, 03:53 PM
Previous filing
Jan 3, 2023
Next filing
Feb 1, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding OFIX Common Stock 70K Jan 5, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding OFIX Employee Stock Option (Right to Buy) Jan 5, 2023 Common Stock 25.8K $37.67 Direct F3, F4
holding OFIX Employee Stock Option (Right to Buy) Jan 5, 2023 Common Stock 26.9K $34.09 Direct F5, F6
holding OFIX Employee Stock Option (Right to Buy) Jan 5, 2023 Common Stock 7.42K $43.82 Direct F7, F8
holding OFIX Employee Stock Option (Right to Buy) Jan 5, 2023 Common Stock 23.2K $28.85 Direct F9, F10
holding OFIX Employee Stock Option (Right to Buy) Jan 5, 2023 Common Stock 2.53K $23.86 Direct F11, F12
holding OFIX Employee Stock Option (Right to Buy) Jan 5, 2023 Common Stock 28.8K $40.50 Direct F13, F14
holding OFIX Employee Stock Option (Right to Buy) Jan 5, 2023 Common Stock 18K $30.44 Direct F15, F16
holding OFIX Employee Stock Option (Right to Buy) Jan 5, 2023 Common Stock 9.04K $36.04 Direct F15, F17
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 27,323 shares of unvested restricted stock units, of which 5,761 unvested restricted stock units vest in equal installments on each of January 28, 2023 and 2024 and 21,562 unvested restricted stock units vest in equal installments on each of February 28, 2023, 2024 and 2025.
F2 Acquired pursuant to the terms of the merger between the Issuer and SeaSpine Holdings Corporation ("SeaSpine") which became effective on January 5, 2023 (the "Merger"), in exchange for 168,198 shares and unvested restricted stock units of SeaSpine, shares having a market value of $22.76 per share at the effective time of the Merger.
F3 The option vested as to 25% of the underlying shares on May 1, 2016 and the remaining 75% vested in twelve substantially equal quarterly installments thereafter.
F4 The option was assumed by Issuer in connection with the Merger and replaced 62,000 SeaSpine options with an exercise price of $15.68.
F5 The option vested as to 25% of the underlying shares on March 31, 2016 and the remaining 75% vested in twelve substantially equal quarterly installments thereafter
F6 The option was assumed by Issuer in connection with the Merger and replaced 64,559 SeaSpine options with an exercise price of $14.19.
F7 The option vested as to 25% of the underlying shares on January 1, 2020 and the remaining 75% vested or vests, as applicable, in twelve substantially equal quarterly installments thereafter.
F8 The option was assumed by Issuer in connection with the Merger and replaced 17,818 SeaSpine options with an exercise price of $18.24.
F9 The option vested as to 25% of the underlying shares on January 1, 2021 and the remaining 75% vested or vests, as applicable, in twelve substantially equal quarterly installments thereafter.
F10 The option was assumed by Issuer in connection with the Merger and replaced 55,746 SeaSpine options with an exercise price of $12.01.
F11 The option fully vested and became exercisable on June 21, 2020.
F12 The option was assumed by Issuer in connection with the Merger and replaced 6,089 SeaSpine options with an exercise price of $9.93.
F13 The option vests as to 25% of the underlying shares on January 28, 2022 and the remaining 75% vests in twelve substantially equal quarterly installments thereafter.
F14 The option was assumed by Issuer in connection with the Merger and replaced 69,128 SeaSpine options with an exercise price of $16.86.
F15 The option vests as to 25% of the underlying shares on February 28, 2023 and the remaining 75% vests in twelve substantially equal quarterly installments thereafter.
F16 The option was assumed by Issuer in connection with the Merger and replaced 43,163 SeaSpine options with an exercise price of $12.67.
F17 The option was assumed by Issuer in connection with the Merger and replaced 21,704 SeaSpine options with an exercise price of $15.00.